HSBC Holdings’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,991
Closed -$66K 2757
2025
Q2
$66K Buy
3,991
+2,757
+223% +$47.6K ﹤0.01% 2908
2025
Q1
$22.3K Hold
1,234
﹤0.01% 2964
2024
Q4
$46.5K Hold
1,234
﹤0.01% 2999
2024
Q3
$39.8K Buy
+1,234
New +$68.5K ﹤0.01% 2904
2022
Q3
Sell
-1,142
Closed -$252K 2955
2022
Q2
$252K Buy
1,142
+627
+122% +$210K ﹤0.01% 2738
2022
Q1
$287K Buy
515
+150
+41% +$90.7K ﹤0.01% 2780
2021
Q4
$248K Buy
+365
New +$279K ﹤0.01% 2911
2021
Q3
Sell
-547
Closed -$695K 2999
2021
Q2
$695K Buy
+547
New +$617K ﹤0.01% 1970
2021
Q1
Sell
-249
Closed -$356K 2770
2020
Q4
$356K Sell
249
-42
-14% -$44.8K ﹤0.01% 2452
2020
Q3
$206K Sell
291
-111
-28% -$80.7K ﹤0.01% 2453
2020
Q2
$281K Buy
+402
New +$232K ﹤0.01% 2165

Other funds holding CDLX

HSBC Holdings's CDLX Position: Q3 2025 in Review

HSBC Holdings sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 3,991 shares — an estimated $66K sold.

HSBC Holdings first reported a position in CDLX in Q2 2020 and held it in 11 quarters. The position peaked at $695K in Q2 2021. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.

  • HSBC Holdings reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 3,991 Cardlytics shares in Q3 2025, an estimated $66K.
  • HSBC Holdings first reported a position in Cardlytics in Q2 2020 and held it in 11 quarters.
  • HSBC Holdings's Cardlytics position peaked at $695K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.